サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551560

コンピュータ支援創薬の世界市場

Computer-Aided Drug Discovery

出版日
ページ情報
英文 375 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
コンピュータ支援創薬の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 375 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

コンピュータ支援創薬の世界市場は2030年までに71億米ドルに達する見込み

2023年に36億米ドルと推定されるコンピュータ支援創薬の世界市場は、2023年から2030年にかけてCAGR 9.9%で成長し、2030年には71億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるリガンドベース設計は、CAGR 10.7%を記録し、分析期間終了までに32億米ドルに達すると予測されます。構造ベースの設計分野の成長率は、分析期間中CAGR9.5%と推定されます。

米国市場は9億9,390万米ドルと推定、中国はCAGR13.7％で成長予測

米国のコンピュータ支援創薬市場は、2023年に9億9,390万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは13.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.3%と8.5%と予測されています。欧州では、ドイツがCAGR 7.9%で成長すると予測されています。

世界のコンピュータ支援創薬市場- 主要動向と促進要因のまとめ

コンピュータ支援創薬の仕組みとコア技術とは？

コンピュータ支援創薬（CADD）は、計算手法を活用して、従来は時間とコストのかかる創薬プロセスを加速し、洗練させる最先端のアプローチです。CADDの核となるのは、高度なアルゴリズムとシミュレーションを駆使して、潜在的な創薬候補物質とタンパク質や酵素などの生物学的標的との相互作用をモデル化することです。このプロセスはターゲットの特定から始まり、次に膨大な化合物ライブラリーをスクリーニングし、ターゲットと効果的に結合し、その活性を調節する可能性を分析します。分子ドッキング、分子動力学シミュレーション、定量的構造活性相関（QSAR）モデリングなどの技術は、このプロセスにおいて極めて重要な役割を果たしています。例えば分子ドッキングは、薬物分子が標的部位にどのように適合するかを予測し、分子動力学シミュレーションは、薬物と標的の複合体の安定性と経時的挙動に関する洞察を提供します。QSARモデリングは、化学構造に基づいて化合物の生物学的活性を予測するのに役立ちます。これらの計算ツールは、創薬の初期段階を効率化するだけでなく、薬物動態学的および毒性プロファイルを予測することによってリード化合物の最適化を可能にし、最終的に、より効果的で安全な医薬品を生み出すことにつながります。

誰がコンピュータ支援創薬の恩恵を受け、どのように製薬研究を変革しているのか？

コンピュータ支援創薬の恩恵は、製薬業界、学術研究機関、そして最終的には、新しい効果的な治療法への迅速なアクセスによって利益を得る患者にまで及びます。製薬会社は、新薬の上市という莫大な資金と時間のプレッシャーに直面していますが、CADDが提供する効率化によって大きな利益を得ることができます。実験室での大規模な実験の必要性を減らし、何百万もの化合物の迅速なスクリーニングを可能にすることで、CADDは有望な医薬品候補の同定を加速し、医薬品開発に関連する時間とコストの両方を削減します。また、学術研究者はCADDを活用して新たな治療標的や作用機序を探索し、従来の方法では治療が困難であった疾患に対する革新的な薬剤の発見につなげています。患者にとっては、CADDの効果は、副作用の少ない、より標的を絞った治療法という形で現れます。計算モデリングの精度は、健康な細胞との相互作用を最小限に抑えながら、病気の原因となる分子と特異的に相互作用するよう調整された薬剤の設計を可能にするからです。その結果、コンピュータ支援創薬は製薬業界を一変させるだけでなく、より個別化された効果的なヘルスケアへの道を切り開こうとしています。

コンピュータ支援創薬の最新の技術革新と動向は？

コンピュータ支援創薬の分野は急速に進化しており、いくつかの新たな動向やイノベーションが製薬研究の未来を形成しています。最も重要な進展の一つは、人工知能（AI）と機械学習（ML）のCADDプロセスへの統合です。AI主導のアルゴリズムは、膨大なデータセットを分析し、パターンを特定し、かつてない精度で医薬品候補の活性を予測することができます。このため、新規化合物の生成や既存化合物の最適化、さらには臨床転帰の予測までを自律的に行うAIベースの創薬プラットフォームが登場しています。もうひとつの動向は、クラウド・コンピューティングとビッグデータ解析の利用拡大です。クラウド・コンピューティングとビッグデータ解析によって、研究者は分散コンピューティングのパワーを活用し、複雑なシミュレーションや大規模データセットの解析をより効率的に行うことができます。量子コンピューティングの台頭は、まだ初期段階とはいえ、原子レベルでの分子間相互作用のシミュレーションを可能にすることで、CADDに革命をもたらし、薬剤の有効性と安全性をより正確に予測できるようになる可能性を秘めています。さらに、ゲノミクス、プロテオミクス、メタボロミクスを含むマルチオミクスデータの利用は、CADDにおいてますます重要性を増しており、疾患メカニズムのより包括的な理解と新薬ターゲットの同定を可能にしています。このような技術革新は、創薬における可能性の限界を押し広げ、より迅速で費用対効果の高い、精度の高い治療法の開発につながっています。

コンピュータ支援創薬市場の成長の原動力は？

コンピュータ支援創薬市場の成長は、製薬業界やバイオテクノロジー業界の継続的な変革を反映するいくつかの要因によって牽引されています。主な要因の1つは、創薬により高度なツールを必要とする疾患生物学の複雑化です。がん、神経疾患、希少遺伝性疾患などの疾患の理解が進むにつれて、これらの複雑な疾患に効果的に対処できる標的療法の必要性が高まっています。特にAI、機械学習、量子コンピューティングなどの技術的進歩により、CADDはより強力で利用しやすくなり、業界全体におけるCADDの採用をさらに促進しています。CADDは創薬プロセスを合理化し、それに伴う財務リスクを軽減するソリューションを提供するため、医薬品開発コストの上昇や新治療の市場投入までの時間を短縮しなければならないというプレッシャーも大きな要因となっています。さらに、遺伝子プロファイルに基づいて個々の患者に合った治療法を開発する必要がある個別化医療への注目の高まりも、特異性が高く有効性の高い医薬品を設計できるCADD技術への需要を後押ししています。製薬会社、学術機関、テクノロジー・プロバイダー間の協力関係の高まりも、イノベーションを促進し、CADDの能力を拡大しています。これらの要因が相まって、コンピュータ支援創薬市場の成長が促進され、将来の医療進歩の重要な原動力として位置づけられています。

調査対象企業の例（全36件）

  • Bayer AG
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Pharmaron Beijing Co., Ltd.
  • BOC Sciences
  • Chemical Computing Group ULC
  • Curia Global, Inc.
  • Bioduro-Sundia
  • Aaranya Biosciences Pvt. Ltd.
  • Aris Pharmaceuticals, Inc;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26768

Global Computer-Aided Drug Discovery Market to Reach US$7.1 Billion by 2030

The global market for Computer-Aided Drug Discovery estimated at US$3.6 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Ligand-based Design, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the Structure-based Design segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$993.9 Million While China is Forecast to Grow at 13.7% CAGR

The Computer-Aided Drug Discovery market in the U.S. is estimated at US$993.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Global Computer-Aided Drug Discovery Market - Key Trends and Drivers Summarized

How Does Computer-Aided Drug Discovery Work and What Are Its Core Technologies?

Computer-aided drug discovery (CADD) is a cutting-edge approach that leverages computational methods to accelerate and refine the drug discovery process, traditionally a time-consuming and costly endeavor. At its core, CADD involves the use of sophisticated algorithms and simulations to model the interactions between potential drug candidates and biological targets, such as proteins or enzymes. The process begins with the identification of a target, followed by the screening of vast libraries of chemical compounds, which are analyzed for their potential to bind effectively with the target and modulate its activity. Technologies such as molecular docking, molecular dynamics simulations, and quantitative structure-activity relationship (QSAR) modeling play pivotal roles in this process. Molecular docking, for instance, predicts how a drug molecule will fit into a target site, while molecular dynamics simulations provide insights into the stability and behavior of the drug-target complex over time. QSAR modeling helps in predicting the biological activity of compounds based on their chemical structure. These computational tools not only streamline the early stages of drug discovery but also allow for the optimization of lead compounds by predicting their pharmacokinetic and toxicity profiles, ultimately leading to more effective and safer drugs.

Who Benefits from Computer-Aided Drug Discovery and How Is It Transforming Pharmaceutical Research?

The benefits of computer-aided drug discovery extend across the pharmaceutical industry, academic research institutions, and ultimately, patients who stand to gain from faster access to new and effective treatments. Pharmaceutical companies, faced with the immense financial and time pressures of bringing new drugs to market, benefit significantly from the efficiency gains offered by CADD. By reducing the need for extensive laboratory experimentation and enabling the rapid screening of millions of compounds, CADD accelerates the identification of promising drug candidates, reducing both the time and cost associated with drug development. Academic researchers also leverage CADD to explore novel therapeutic targets and mechanisms of action, often leading to the discovery of innovative drugs for conditions that have been challenging to treat with conventional methods. For patients, the impact of CADD is seen in the form of more targeted therapies with fewer side effects, as the precision of computational modeling allows for the design of drugs that are tailored to interact specifically with disease-causing molecules while minimizing interactions with healthy cells. As a result, computer-aided drug discovery is not only transforming the pharmaceutical landscape but also paving the way for more personalized and effective healthcare.

What Are the Latest Innovations and Trends in Computer-Aided Drug Discovery?

The field of computer-aided drug discovery is rapidly evolving, with several emerging trends and innovations shaping the future of pharmaceutical research. One of the most significant developments is the integration of artificial intelligence (AI) and machine learning (ML) into the CADD process. AI-driven algorithms are capable of analyzing vast datasets, identifying patterns, and predicting the activity of drug candidates with unprecedented accuracy. This has led to the emergence of AI-based drug discovery platforms that can autonomously generate novel compounds, optimize existing ones, and even predict clinical outcomes. Another trend is the increasing use of cloud computing and big data analytics, which allow researchers to harness the power of distributed computing to perform complex simulations and analyze large datasets more efficiently. The rise of quantum computing, though still in its early stages, holds the potential to revolutionize CADD by enabling the simulation of molecular interactions at an atomic level, leading to more accurate predictions of drug efficacy and safety. Additionally, the use of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly important in CADD, enabling a more comprehensive understanding of disease mechanisms and the identification of new drug targets. These innovations are pushing the boundaries of what is possible in drug discovery, leading to faster, more cost-effective, and more precise therapeutic development.

What Is Driving the Growth of the Computer-Aided Drug Discovery Market?

The growth in the computer-aided drug discovery market is driven by several factors that reflect the ongoing transformation of the pharmaceutical and biotechnology industries. One of the primary drivers is the increasing complexity of disease biology, which demands more sophisticated tools for drug discovery. As diseases like cancer, neurological disorders, and rare genetic conditions become better understood, there is a growing need for targeted therapies that can address these complex conditions effectively. Technological advancements, particularly in AI, machine learning, and quantum computing, are making CADD more powerful and accessible, further driving its adoption across the industry. The rising cost of drug development and the pressure to reduce time-to-market for new therapies are also significant factors, as CADD offers a solution that can streamline the drug discovery process and reduce the financial risks associated with it. Additionally, the growing focus on personalized medicine, which requires the development of therapies tailored to individual patients based on their genetic profiles, is fueling demand for CADD technologies that can design drugs with high specificity and efficacy. The increasing collaboration between pharmaceutical companies, academic institutions, and technology providers is also fostering innovation and expanding the capabilities of CADD. Together, these factors are propelling the growth of the computer-aided drug discovery market, positioning it as a key driver of future advancements in medicine.

Select Competitors (Total 36 Featured) -

  • Bayer AG
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Pharmaron Beijing Co., Ltd.
  • BOC Sciences
  • Chemical Computing Group ULC
  • Curia Global, Inc.
  • Bioduro-Sundia
  • Aaranya Biosciences Pvt. Ltd.
  • Aris Pharmaceuticals, Inc ;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Computer-Aided Drug Discovery - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Complexity of Disease Mechanisms Expands Addressable Market Opportunity for Advanced CADD Tools
    • Integration of Artificial Intelligence and Machine Learning Spurs Growth in Computer-Aided Drug Discovery Market
    • Advancements in High-Performance Computing Propel Adoption of Computer-Aided Drug Discovery Solutions
    • Increasing Use of Big Data Analytics in Drug Development Accelerates Demand for Computational Approaches
    • Emergence of Cloud-Based Solutions Expands Access to Computer-Aided Drug Discovery Resources
    • Rising Pressure to Reduce Drug Development Costs and Time-to-Market Sustains Growth in CADD Applications
    • Here's How Advances in Quantum Computing Are Poised to Revolutionize Computer-Aided Drug Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Computer-Aided Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Ligand-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Structure-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sequence-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • JAPAN
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CHINA
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • EUROPE
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Computer-Aided Drug Discovery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • FRANCE
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • GERMANY
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • INDIA
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Computer-Aided Drug Discovery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Computer-Aided Drug Discovery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AFRICA
    • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030

IV. COMPETITION